What Clinical Sequencing Needs

What Clinical Sequencing Needs

Despite the advances in NGS technologies, their successful application and translation to clinical diagnostics must overcome various challenges, detailed in this article.


China's IVD Market: An Opportunity For Surplus Revenue Growth

China's IVD Market: An Opportunity For Surplus Revenue Growth

China represents the most attractive IVD market in the developing world and among developing nations. Additionally, the Chinese IVD market has been and is projected to be the fastest growing among the top-ten national IVD markets. This article describes the opportunity in China and the reasons it's market continues to show better-than-world-average growth.


The CRISPR Diagnostic Toolkit Gets Handier

The CRISPR Diagnostic Toolkit Gets Handier

A new platform based on the gene editing technique is unveiled, and an old-but-still-pretty-new method gets an update. Plus, a CRISPR-related retraction.


Outsourced Drug Discovery Market is Up 17% Per Our Eighth Edition Study of the CRO Market

Outsourced Drug Discovery Market is Up 17%  Per Our Eighth Edition Study of the CRO Market

Increased demand for pharmaceutical "blockbusters," or even middle-of-the-road revenue earners, is fueling the need for outsourcing. Patent expiration and increased demand for R&D, when many firms have laid off workers in R&D, adds up to business for CROs. A trend we've been noticing since 2002. Current status in our most recent report.

  • by Bruce Carlson
  • March 16 2018


Theranos a Note of Caution on Company Hype

Theranos a Note of Caution on Company Hype

Using filtered publications, such as market research publications that can analyze company promises and how results shape up with the overall market can be helpful. No case proves that more than Theranos, a company that was valued by investors to be 8-20% of the market for its potential services, and as large as established players when it had barely seen a product approval.

  • by Bruce Carlson
  • March 15 2018


Why Kalorama Does Not Publish 100s of Studies Each Year

Patient study of medtech, biotech and IVD markets takes time. Beware of firms that publish in a wide range of areas and firms that publish hundreds of studies each year. Our studies take months to complete and involve consideration of all products on the market and consensus establishment and verification of multiple sources. Firms that publish 100s of studies each year cannot make a convincing investigation of healthcare markets.

  • by Bruce Carlson
  • March 8 2018


Direct-to-Consumer Diagnostic Testing Has Arrived, With First Cancer Risk Test

Direct-to-Consumer Diagnostic Testing Has Arrived, With First Cancer Risk Test

the FDA has approved 23andMe's BRCA 1 and 2 test for use without a prescription, in what we see as a positive sign for the $99M direct-to-consumer market.

Now come the challenges.


Point of Care Growth - Beware of Over-Optimistic Growth Estimates

Point of Care Growth - Beware of Over-Optimistic Growth Estimates

Double-digit growth rates seen on the Internet may not be taking account important factors - such as currency effects, decreased glucose spending and pricing in developed nations and centralization of testing in Europe. In this article we explain why a 4.9% CAGR is appropriate for this market area.


"Direct-To-Consumer" Genetic Testing - Market Expected to Triple in Five Years

Patient is king when it comes to certain types of testing, especially genetic tests. A new report from Kalorama Information finds fast growth in direct-to-consumer testing.

  • by Bruce Carlson
  • February 21 2018


Four Things to Know About The Monoclonal Antibodies – “mAbs” Market

From the best region for sales to the best type of Monoclonal Antibodies, this article provides 4 points about the market, as developed in our report. This according to our report, according to Kalorama Information's new report What's Trending in Monoclonal Antibodies.